Holding(s) in Company

DXS International

25/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230525:nGNE57KtXB&default-theme=true


DXS INTERNATIONAL PLC

Holding in Company and Total Voting Rights

The Board of DXS International plc (the “Company”), the AQSE Growth Market
quoted clinical decision support developer and supplier of clinical decision
support systems has received notification under the DTR that following the
Placing announced on 17 May 2023, the following persons have voting rights in
the Company as follows:

 3. Details of person subject to the notification obligation (iv)                                                                                                                                                                                                                                                
 Name                                                                                                                                                                     Foresight Group LLP                                                                                                                    
 City and country of registered office (if applicable)                                                                                                                    London, UK                                                                                                                             
 4. Full name of shareholder(s) (if different from 3.) (v)                                                                                                                                                                                                                                                       
 Name                                                                                                                                                                     Thames Ventures VCT 1 plc                                                                                                              
 City and country of registered office (if applicable)                                                                                                                    London, UK                                                                                                                             
 5. Date on which the threshold was crossed or reached (vi):                                                                                                              24.05.23                                                                                                                               
 6. Date on which issuer notified (DD/MM/YYYY):                                                                                                                           24.05.23                                                                                                                               
 7. Total positions of person(s) subject to the notification obligation                                                                                                                                                                                                                                          
                                                                            % of voting rights attached to shares (total of 8. A)  % of voting rights through financial instruments (total of 8.B 1 + 8.B 2)     Total of both in % (8.A + 8.B)  Total number of voting rights held in issuer (8.A + 8.B) (vii)  
 Resulting situation on the date on which threshold was crossed or reached  11.71                                                  11.71                                                                                                         7,500,000                                                       
 Position of previous notification (if  applicable)                         n/a                                                    n/a                                                                           n/a                                                                                             



 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached (viii)                
 A: Voting rights attached to shares                                                                                            
 Class/type of shares  ISIN code (if possible)  Number of voting rights (ix)            % of voting rights                      
                                                Direct  (DTR5.1)  Indirect  (DTR5.2.1)  Direct  (DTR5.1)  Indirect  (DTR5.2.1)  
 GB00B2Q6HZ92                                   7,500,000         n/a                   11.71             n/a                   
                                                                                                                                
                                                                                                                                
 SUBTOTAL 8. A                                  7,500,000                               11.71                                   

In accordance with the FCA's Disclosure Guidance and Transparency Rules, as at
24 May 2023 the Company's issued share capital consists of 64,022,124 Ordinary
Shares of 0.33pence each, each with one voting right. The Company does not
hold any Ordinary Shares in treasury. Therefore, the total number of voting
rights in the Company is 64,022,124.

The above figure of 64,022,124 should be used by shareholders in the Company
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in,
the share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

The Directors of DXS International plc accept responsibility for this
announcement

Enquiries:

 David Immelman (Chief Executive) DXS International plc      01252 719800 david@dxs-systems.com  
 Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS                                      
 www.dxs-systems.co.uk                                                                           



 Corporate Advisor                              
 David Papworth City & Merchant  0207 101 7676  



 Corporate Broker                                 
 Hybridan LLP Claire Louise Noyce  020 3764 2341  

Note to Editors:

DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other trusted NHS
sources, to doctors, nurses and pharmacists in their workflow and during the
patient consultation. This effective clinical decision support ultimately
translates to improved healthcare outcomes delivered more cost effectively
which should significantly contribute towards the NHS achieving its projected
efficiency savings